New safety check for rare disease treatment in india
NCT ID NCT05067868
Summary
This study aims to learn more about the safety and effects of an enzyme replacement therapy called Replagal in Indian children and adults with Fabry disease, a rare genetic disorder. Participants who have not taken Replagal before will receive it as an infusion at a clinic every two weeks for about one year. The main goal is to monitor for any side effects while also checking if the treatment helps with kidney function, heart health, pain, and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
All India Institute of Medical Sciences (AIIMS)
RECRUITINGNew Delhi, 110029, India
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institute of Child Health
NOT_YET_RECRUITINGKolkata, 700017, India
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sir Gangaram Hospital
RECRUITINGNew Delhi, 110060, India
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.